Acetylspiramycin

Acetylspiramycin (Spiramycin B) is an effective oral macrolide antibiotic produced by Streptomyces, It can inhibit the splenic lymphocyte transformation induced by phytohemagglutinin (PHA), LPS (HY-D1056) and antigen, reduce the procoagulant activity of macrophages, have good antibacterial effect on gram-positive bacteria, and is also an effective antigenic insect agent, which can be used to fight parasitic infection^[1][2][3][4]. IC50 & Target:Bacterial^[1] In Vitro:Acetylspiramycin (0-40 μg/mL, 0-72 h) can dose-dependently inhibit lymphocyte proliferation in spleen cell culture medium supplemented with plant hemagglutinin (PHA, 10 μg/mL), and the extent of its effect depends on the time of addition^[3].
Acetylspiramycin (25-100 μg/ml, 18 h) can reduce the phagocytosis of mouse peritoneal macrophages and has reversible toxicity to macrophages in vitro^[4].
In Vivo:Acetylspiramycin (25-200 mg/kg/day; Oral gavage (p.o.); 7 days) can significantly enhance the lymphocyte proliferation response of CBA/H mice to PHA, and reduce the activity of lymphokine in a dose-dependent manner^[3].
Acetylspiramycin (50-200 mg/kg/day; Oral gavage (p.o.); 14 days) in CBA/H mouse models can increase the efficiency of phagocytosis in mice^[4].